In 1902 Bayliss & Starling carried out a series of experiments that must rank as endocrinology's equivalent of man's first lunar footsteps. Pawlow and others had previously shown that the flow of pancreatic juice started with the entry of acid chyme into the duodenum, and attributed this to reflex secretion following the passage of nervous impulses from the duodenal mucosa to the pancreas. In what they described as 'an experimentum crucis', Bayliss & Starling isolated a loop of jejunum of an anaesthetized dog, injected dilute hydrochloric acid into the lumen and evoked increased flow of pancreatic juice. 'The next step in our experiment was plain', they said -in what must be one of science's greater understatements: They cut off the loop of jejunum, scraped off the mucous membrane, rubbed it in a mortar with 0.4% HCI and sand, filtered it through cotton-wool to get rid of lumps and the sand, and injected the extract into the dog's vein. After 70 seconds pancreatic flow increased dramatically. This demonstration of a chemical substance, which they called secretin, formed in the mucous membrane of the upper small intestine under the influence of acid and carried by the bloodstream to excite the pancreas was to form the basis of endocrine thinking for the next 60 years.
It is the concept of a hormone as something synthesized, secreted, transported to and acting on a target cell that I wish to discuss. For nothing is ever as simple as it first seems. And we now know that what is synthesized by a cell is not necessarily what is secreted by it; what is secreted by a cell is not necessarily what reaches the target; and what reaches the target is not necessarily what acts on it. I propose to take examples of the major hormone species, to consider what might happen between synthesis and action, and to discuss some implications of this 'peripheral modulation'.
Protein hormone --insulin I select insulin as a model of a protein hormone because it allows me to review two aspects of metabolism common to other protein hormones, e.g. parathyroid hormone (PTH) and glucagon, relatively new in concept and of some clinical significance: (I) Prohormone synthesis.
(2) Receptor interactions.
Proinsulin
In the last 10 years the mechanism of synthesis of insulin has largely been elucidated (Rubenstein et al. 1977) . The large proinsulin molecule is a single chain precursor synthesized on ribosomes in the rough endoplasmic reticulum of the pancreatic /I-cells. Cleavage of the connecting peptide (C-peptide) takes place either in the Golgi region or in immature secretory granules. Insulin, C-peptide and some unconverted proinsulin are stored together in secretory granules to be released during exocytosis. Why prohormones are synthesized is not clear. It has been suggested (a) that ribosomes can only synthesize proteins of a minimum size, and production of smaller units must depend on post-translational modification; (b) that the single chain conformation facilitates insulin formation by ensuring correct pairing of cysteine residues; or (c) that transport through the cell is facilitated. Recent reports of the existence of preproinsulin, analogous in form to preproparathormone, suggest that even proinsulin may be smaller than the originally synthesized molecule.
Immunoassays have been developed for proinsulin and C-peptide as well as insulin, and all three can be shown to be secreted by the pancreatic {J-cell. An increased circulating proinsulinJinsulin ratio is found in old age, severe hypokalaemia, severe diabetes and in chronic renal failure, but the main value of proinsulin assay seems to lie in the detection of pancreatic islet cell tumours in which both absolute and percentage proinsulin is elevated in the serum (Rubenstein et al. 1977) . No clear distinction is found, however, between benign and malignant tumours.
Of interest is a recent report of familial hyperproinsulinaemia in which up to 95% of circulating immunoassayable insulin is proinsulin (Gabbay et al. 1976) . The condition, inherited as an autosomal dominant, appears to be asymptomatic. A defect in proinsulin synthesis, cleavage or both, is postulated.
Insulin and C-peptide are released by the fJ-cell in equimolar concentrations but differences in metabolic clearance rate, including first-pass hepatic extraction, result in serum ratios that are not equimolar. Because of the development of antibodies to exogenous insulin which interfere with the assay of endogenous insulin, it is difficult to study fJ-celi secretory capacity in insulin-treated diabetics. Such antibodies do not cross-react with C-peptide, assay of which may provide a means of assessing fJ-cell reserve.
In a test for insulinomas analogous to that devised by Turner & Johnson (1973) using fish insulin, assay of C-peptide can be used to demonstrate non-suppressibility of endogenous insulin secretion during porcine insulin-induced hypoglycaemia (Horwitz et al. 1975). Finally, suppression of circulating C-peptide has been shown in cases of hypoglycaemia due to surreptitious injection of insulin.
Insulin receptors
Binding of protein and polypeptide hormones to surface receptors is a necessary preliminary to their action, but is not always followed by it; recognition and binding may take place without consequent biological activity. Appreciation of a possible modulating role of receptors has explained several anomalous findings. In obesity, for instance, serum insulin concentration is elevated. This insulin can be shown to contain normal proportions of proinsulin and insulin and to be biologically competent; yet obese patients are not hypoglycaemic. Resistance to exogenous insulin is also exhibited. The paradox is explained by a deficiency of binding to receptor sites due to decrease in their number (Roth et al. 1977) .It is not clear whether the loss of receptors is a primary or secondary defect. A metabolic block in intracellular oxidation of glucose has been proposed in obese subjects, as a consequence of which the blood sugar fails to respond normally to insulin, and hypersecretion of the hormone occurs. Insulin has been shown to reduce the number of its own cell surface receptors. This sequence could explain the abnormalities found in obese subjects. Reduction of circulating insulin levels (following food restriction, for example) leads to restoration of insulin receptors and return of insulin sensitivity. Similar insulin resistance associated with decreased binding has been found in maturity-onset diabetes and in acanthosis nigricans.
Insulin receptors may modulate the effects of insulin in two other ways: firstly, through the development of anti-receptor antibodies in some subjects (Flier et al. 1976 )(resulting in insulin resistance); and, second but rarely, through the postulated ability of surface receptors themselves, at least of liver cells, to degrade insulin. Much has been written about initiation of hormone action, little about termination. Degradation at binding sites would offer an ingenious device for this step. This new view of insulin illustrates two recently-recognized aspects of protein hormone biochemistry. What is synthesized is often altered before it is secreted, and what is secreted and reaches the cell may not reflect what acts upon it. The clinical implications of these concepts are just beginning to unfold.
Glycoprotein hormone -thyroid stimulating hormone (TSH)
The glycoprotein hormones (TSH, FSH, LH and HCG) consist of non-covalently bound dissimilar ex and fJ subunits. The ex subunit is identical or almost identical for all 4 hormones, the fJ subunits differ from one another and confer specificity of action. Subunits of individual hormones may be dissociated and recombined to give high if not full biological activity, and may be interchanged to give hybrids having only the character of the hormone from which the fJ subunit was obtained. Thus, TSH fJ combined with TSH a, LH a or HCG a has TSH-like activity. The dissociated subunits are devoid of biological activity in vitro or in vivo and may be measured independently by radioimmunoassay. Both a and Iisubunits, in addition to complete TSH, are present in increased concentration in the serum of hypothyroid subjects and may be suppressed by administration of thyroid hormones or increased by TRH injection (Kourides et al. 1973 , Kourides, Re et al. 1977 . Evidence suggests that the subunits and whole molecule are synthesized and stored in the pituitary gland in which an excess of a subunit may usually be demonstrated. Subunits in serum are derived from pituitary secretion not peripheral breakdown of the parent molecule.
Secretion of protein hormones (growth hormone, prolactin, ACTH) by pituitary tumours is often documented, but glycoprotein secretion is far less commonly found. A recent study of 57 men with pituitary adenomas revealed 13 (23%) with basal or stimulated serum FSH that was higher than normal controls and FSH hypersecretion was assumed (Snyder et al. 1978) . Unbalanced or isolated subunit secretion is a well-documented feature of some pituitary tumours, analogous perhaps to the unbalanced production of immunoglobulin chains by some plasma cell neoplasms. In 60 patients with pituitary adenomas Kourides et al. (1976) found 5 with elevated serum a-subunit which showed little or no response to TRH or LHRH injection.
In 6 patients with hyperthyroidism and inappropriate TSH secretion, a secretion was shown to be excessive (Kourides, Ridgeway et al. 1977) .
In 1974 Rosen & Weintraub reported a patient with metastatic gastric carcinoid in whose serum and tumour extract high concentrations of a subunit were present; comparable amounts of Ii subunit or intact glycoprotein hormone could not be found. This paved the way for more extensive studies of carcinomas in general and Odell & Wolfsen (1978) have found that 41%of patients with mixed carcinomas had elevated serum a subunit concentration. Since subunits have no biological activity and, indeed, do not bind to hormone receptors, a-chain secretion by cancers produces no symptoms. It may, however, serve as a useful marker of response to treatment, recurrence or spread of the disease. In our own laboratories a subunit has been detected in the cytosol of about 40% of breast cancers studied in vitro by radioimmunoassay (RIA) and immunoperoxidase staining, but in less than 20~~of the same patients' sera (Cove et al. 1979) . Serum IX chain detection has not so far proved useful as a diagnostic aid.
Little has been written about the peripheral metabolism of glycoprotein hormones. TSH is rapidly degraded by many tissues in the body, not specifically those possessing a surface binding receptor for the hormone. Kohn & Win and (1975) have recently postulated a role for a TSH-product in the pathogenesis of exophthalmos. The demonstration by specific RIA of low levels of TSH in exophthalmic thyrotoxic patients and the absence of exophthalmos in hypothyroid subjects with high circulating TSH seemed satisfactorily to dispose of the theory that exophthalmos was caused by TSH. Kohn and Winand claim to have isolated an exophthalmogenic factor consisting of a {J-subunit of TSH and a fragment of «-subunit, but confirmation of this suggestion and information about the molecule's origin are still awaited.
The thyroid receptor for TSH has been the subject of fruitful research and its exploitation in the development of receptor assays for thyroid stimulating immunoglobulins has had farreaching effects. But little is yet known of the regulation of receptor concentration or its modulation ofTSH action; degradation ofTSH does not seem to be a property of its receptors.
In the case of glycoproteins most of what is synthesized is secreted; unbalanced secretion of subunits by the pituitary may occur and inappropriate secretion of IX chain is a feature of some carcinomas. Peripheral metabolism of these hormones does not seem important.
Large peptide --ACT" Few revelations have been quite so exciting as those about ACTH over the past five or so years. The close association between ACTH and MSH secretion has been a dogma cherished by all who wished to provide an easy, if not fully understood, explanation for the pigmentation of Addison's disease. The disclosure that MSH is an artefact has come as a great shock to traditionalists of my generation (Bloomfield et al. 1974) .
A recent review by Lesley Rees (1977) , from which I have drawn freely, shows the structural relationship between a variety of pituitary peptides. Broadly speaking these break down into 2 groups, related to ACTH and to lipotropin (LPH). A common hepta peptide -met-glu-hisphe-arg-trp-gly -occupies residues 4-10 of ACTH and et-MSH, and 46-52 of the {J-MSH group, providing a structural link between two biologically related species.
In the human adult et-MSH, CLIP and {J-MSH are not normally found; they occur in the pituitaries of lower vertebrates, in the human fetus and perhaps in the pregnant female, in general only in species with a pars intermedia lobe.
In 1971 Yalow & Berson described the presence in human pituitaries and plasma, and in ectopic ACTH-producing tumours, of a large molecular weight form of ACTH, immunoreactive but possessing only about 3% of the bioactivity of ACTH. On treatment with trypsin, 1-39 ACTH was yielded suggesting that 'big ACTH' was in fact a prohormone. Lowry and coworkers (1977) have now suggested that 'big ACTH' is ACTH +(J-LPH, a large precursor which in theory could give rise to at least 7 recognized peptides. Himsworth and colleagues (1977) have described ectopic production of 'big ACTH' by a tumour of the lung.
In general, ACTH and LPH secretion parallel one another but there are occasional instances of dissociation, for instance in renal failure patients on chronic dialysis programmes; the reason for this is not clear but a difference in metabolic clearance rates of the two hormones has been proposed.
Perhaps the most exciting facet of this fascinating group of peptides has been the recognition of the new class of opiate agonists, the enkephalins and fJ-endorphin. The latter, structurally related to the larger (J-LPH molecule, is found in the same pituitary cells and secreted in parallel; it binds strongly to opiate receptors and has potent morphine-like activity. Metenkephalin (residues 61-65 of (J-LPH) is a pentapeptide of considerable potential importance in our emerging understanding of pain appreciation.
In the case of ACTH, then, evidence for a precursor molecule exists. In theory it could give rise to a family of daughter-products ranging in target-organ response from the familiar control of adrenocortical function to our appreciation of pain and, even, our responses to chronic opiate usage.
Small peptide thyrotrophin releasing hormone (TRH)
The synthesis and widespread availability ofTRH has led to new insights into mechanisms of hypothalamic-pituitary-thyroid control. But little is known with certainty about the control of TRH itself.
The tripeptide is known to be rapidly degraded in serum or plasma, probably by cleavage of the histidyl-proline bond and the prolyl amide. This degradation has been shown to be enzymatic and may regulate the activity of TRH by determining the number of molecules available to the TSH-secreting cells of the pituitary. The activity of the degrading enzyme itself needs regulating, and this might be achieved by variable concentrations of thyroid hormones. In rats made hypothyroid by propylthiouracil (PTU) administration TRH degradation is reduced; treatment with triiodothyronine (T3) restores the rate of degradation to normal or Supra-normal levels (Bauer 1976 ).An ingenious explanation may thus be provided for negative feedback control: high plasma concentrations of thyroid hormones would increase the rate of degradation ofTRH, thereby attenuating the TSH-response and thyroid hormone release, and vice versa.
A further regulatory mechanism has been proposed through modulation of pituitary cell receptors for TRH. The number of these receptors, not their affinity, has been shown to decrease after exposure to TRH and to thyroid hormones (Gershengom et al. 1978) . In this respect, it is interesting to note that T3 and triac have equally potent activity, both considerably greater than that ofT4.
Although TRH has been measured in plasma, of humans as well as experimental animals, the data are hard to interpret. The assay is difficult and it is doubtful whether serum values reflect those found in the hypothalamo-hypophyseal portal veins. The conflicting reports in the literature are unlikely to be resolved until methodological problems are overcome. The metabolism ofTRH needs further elucidation but may provide an example of feedback control exerted peripherally by target hormones on their original stimulator.
Modified amine -thyroxine (T4) It seems probable that thyroxine starts as an inactive hormone and its actions are mediated through its metabolites. Four main peripheral pathways of T4 metabolism have been recognized: (1) Deiodination. (2) Oxidative decarboxylation. (3) Conjugation. (4) Ether cleavage. The most important of these is probably deiodination, a process thought to occur sequentially from T4 to TO (thyronine). Altogether there are 12 deiodinations in this degradative pathway; little is known with certainty about their chemistry. It is likely there are simply two deiodinases for inner and outer ring iodine atoms.
The two first-line products are 3,5,3'-T3 (T3) and 3,5',3'-T3 (reverse T3, rT3). Much has been learned about their production. Of interest has been the growing list of conditions in which T3 production has been shown to be impaired, usually linked to a rise in serum rT3, due either to increased synthesis or decreased clearance. This list includes acute stress (Burr et al. 1975) , acute (Burger et al. 1976 )and chronic illness (Carter et al. 1976 ), starvation (Vagenakis et al. 1975) , liver disease (Nomura et al. 1975 ) and administration of propylthiouracil (Oppenheimer et al. 1972) ,glucocorticoids (Chopra et al. 1973) , propranolol (Lotti et al. 1977) . Similar changes reported in the elderly probably reflect associated illness rather than the ageing process per se. Since T3 is metabolically highly active and rT3 inert, one might ask to what extent these changes are advantageous to the individual. Is it of benefit to have lower circulating T3 concentration (and presumably lower metabolic rate) after stress or in chronic illness?
The response to dietary intake has special implications. With fasting (Vagenakis et al. 1975) or reduced caloric intake (Visser et al. 1978 , Spaulding et al. 1976 , serum T3 concentration falls and rT3 rises. As weight is lost by obese subjects, metabolic rate is decreased (Bray 1969) . In anorexia nervosa a similar reduction of serum T3 is found. Fowler et al. (1972) and Croxson & Ibbertson (1977) have shown prolongation of Achilles reflex response which they felt was a valid indicator of hypothyroidism in this condition. Re-feeding was associated with a rise in serum T3 and a fall in reflex time. After calorie restriction, is a low T3 and low metabolic rate part of the body's attempt to conserve energy? Conversely, when subjects are deliberately 'fattened' by increased caloric intake, serum T3 concentrations rise (Bray et al. 1976) . an attempt to 'burn off' excess calories? These thoughts prompted us to investigate obese subjects treated by simple dietary restriction. In a small series so far studied several patients showed falling weight, serum T3 and oxygen consumption; exhibition of T3 in physiological amounts appeared to elevate serum T3 concentration, increase oxygen consumption and facilitate weight loss but this effect was not sustained. It seems unlikely that changes in peripheral metabolism ofT4 can be blamed for resistance to dietary treatment in obese subjects.
Recognition of the metabolic importance ofT31ed to rapid delineation of the syndrome now known as T3-toxicosis (Sterling et af. 1970) . Less well known but worth mentioning is the recently-described syndrome of'T4-toxicosis', a somewhat mixed bag but a potential source of diagnostic confusion (Stockigt et al. 1978) .
'Compensatory' high serum T3 values are found in a number ofcircumstances, e.g. in iodinedeficient endemic or dyshormonogenetic goitres, autoimmune thyroiditis and Graves' disease after therapy; in the last of these, diagnostic confusion may result from the presence of high serum TSH, low or normal serum T4 but elevation of serum T3. This is an important group of patients to recognize and to follow as it is not yet clear what happens to them. Some, certainly, seem able to maintain this abnormal hormonal status for many years without progressing to hypothyroidism. This aspect has gained in importance now that comprehensive screening pro~rammes for neonatal hypothyroidism are available. The diagnosis is usually based on t~e finding of low serum T4 with or without a high serum TSH concentration, and treatment IS usually instituted. There is good evidence that many neonates (perhaps half) diagnosed as hypothyroid do have functioning thyroid tissue -by isotope scans or assay of serum thyroglobulin or T3. While it seems quite reasonable -in fact desirable -to treat such infants with thyroid hormones, it is equally important to assess them later in childhood to see whether continued therapy is necessary, and particularly to assess the efficacy of hormone replacement in preventing mental deterioration.
Little is written about the role, if any, of other metabolites of thyroxine, many of which are capable of exerting biological effects in a variety of systems. Reverse T3, for instance, is a powerful inhibitor of T4 to T3 monodeiodination, about 100 times as potent as propylthiouracil on a molar basis (Chopra 1977) . This may account for its long-recognized inhibition of the calorigenic effects of T4 (Pittman & Barker 1959) . 3'5'-diiodothyronine, another product of inner-ring deiodination, also inhibits T4 to T3 conversion, and both products may play a role in intracellular regulation of T4 and T3 deiodination. Triiodothyroacetic acid (triac), rT3 and 3,3'-diiodothyronine ('split-T2') all inhibit the TSHsecreting response of anterior pituitary cells after TRH stimulation although the doses required to achieve this effect are above physiological. T3 and T4 are able to stimulate aminoacid uptake by isolated rat thymocytes; in this system rT3 is highly active and split-T2 is as potent as T3 (Goldfine et al. 1976) . Many other activities have been attributed to thyroxine analogues, including stimulation of erythropoiesis in vitro (Golde et al. 1977) .
A word about the locus of action of thyroid hormones. Like the steroid hormones T3 and T4 are thought to enter cells by exchange between serum and cytosol binding proteins; nuclear action seems less dependent on cytosol receptor modulation in the case of thyroid hormones. The nuclear site of action is not in dispute but Sterling & Milch (1975) have produced cogent arguments in favour of an additional mitochondrial locus and Ingbar's group for direct effects on plasma cell membranes (Goldfine et al. 1976) . Tata (1975) supports a ubiquitous distribution of thyroid hormones within the cell with multiple sites and types of response. T4, T3 and rT3 have all been shown to bind to human thyroid plasma membranes, probably at the TSH receptor site, and may have a role in regulating TSH binding and hence its effects.
Response of a cell to thyroid hormone action depends on the number of available receptors and their affinity for each hormonal analogue. Oppenheimer (1975) has shown a good correlation between the metabolic response of different tissues and the T3 binding capacity of their nuclear receptors.
Metabolic responsiveness to a particular analogue is thought to depend on its time of occupancy of a constant level of receptors in each cell nucleus. Triac is bound to the nucleus at least as strongly as T3, yet has lower biological activity in most assays; this is explained by its shorter time of occupancy of receptors, due to its more rapid degradation within the cell.
Based on such postulates Oppenheimer, DeGroot and others (Oppenheimer 1975 have proposed a general theme to account for relative potencies of different hormones and the degree of responsiveness of different target organs. It is interesting that different organs may respond differently to the same stimulus. C:avalieri and colleagues have reported opposite effects of glucose on deiodinases in liver and kIdney (Gavin et al. 1978) .
Much has been learned in recent years about the peripheral metabolism ofT4. It is tempting to regard the complex and interacting pathways as part of a purposeful system to regulate the responses of the body as a whole or in part to an important metabolic hormone. Whether this is a purposeful system or simply accidental entry of thyroid hormones into metabolic pathways not essential for their action or disposal is unclear. What does emerge is that what leaves the thyroid gland and is measured in the serum may not reflect what is happening within the cell, and that extrathyroidal factors may be more important in determining the overall thyroid status of the individual.
Non-aminoacid-derived sterol vitamin D The classical vitamin D compounds cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) are not metabolically active and undergo a series of hydroxylations to reach met aboli-cally active forms. Appreciation of these pathways has led to new understanding of physiological control as well as therapeutic benefit (Haussler & McCain 1977 , DeLuca 1976 , Habener & Mahaffey 1978 .
Defective 25-hydroxylation is thought to occur in some cases of severe liver disease and as a side effect of anticonvulsant therapy. But the picture is still not clearly understood and the evidence not conclusive.
In severe renal disease complex patterns of bone disease occur; in some cases resistance to conventional doses of vitamin D is observed. Plasma 25(OH)D3 levels may be normal but 1,25(OHhD 3 subnormal, suggesting deficient l-hydroxylase activity; treatment with la(OH)D 3 or 1,25(OHhD 3 may then be effective. Some giant cell tumours of bone or other mesenchymal tumours may produce an inhibitor of lc-hydroxylase leading to a similar form of osteomalacia.
Perhaps the crux of these new discoveries is the emergence of renal Ie-hydroxylase as the principal site of regulation of vitamin D metabolism and, although much remains to be clarified, phosphate as the dominant factor in its regulation. The concentration of phosphate within the renal cell appears crucial to control of the enzyme and it is likely that the effects of hypocalcaemia and parathyroid hormone are mediated via intracellular phosphate concentration. The role of other hormones is less well defined.
A practical consequence of our new insight into vitamin D metabolism is the development of therapeutic analogues capable of bypassing metabolic blocks, such as 25(OH)D 3 , la(OH)D 3 and 1,25(OHhD 3 . One might question whether la(OH)D 3 in particular is not being a little overused in circumstances where its special characteristics are not required.
In looking at the complexities of vitamin D metabolism I have neglected the products of 24and 26-hydroxylation and the interesting 1,24,25-trihydroxy metabolite. Their role, if any, is still uncertain but a suggestion of differential action on bone and gastrointestinal tract holds promise of therapeutic benefits.
Enough has emerged in the past ten years to show our total dependence on peripheral metabolism in the case of vitamin D, and to provide the first example of elevation of a vitamin to hormonal status through elucidation of its peripheral pathways.
Non-aminoacid-derived steroid oestrogens My willingness to trample over fields where wiser men would fear to tread has probably gone far enough: I do not plan to discourse on the peripheral metabolism of oestrogens. I include them to illustrate a single point -the way in which, through its actions, one hormone can modulate the effects of another.
As a preliminary to their cellular action oestrogens are bound to cytoplasmic receptors (ER). Assay of these receptors in breast tumours provides useful information about prognosis and possible management. Some 60~~of tumours with ER respond to hormone therapy but only 8 16% of ER-negative (British Medical Journal 1978) . It has been suggested that integrity of the whole intracellular pathway of oestrogen action is necessary for therapy to succeed; in other words, cytoplasmic receptor must be present but in addition, translocation of the oestrogenreceptor complex to the nucleus must take place as well as stimulation of a nuclear endproduct. Integrity of this pathway may be demonstrated by assaying tumours for oestrogendependent products such as lactalbumin (Woods et al. 1977) , an approach which seems to offer some hope of rationalizing endocrine treatment. Oestrogens also control the synthesis of progesterone receptors (PgR) in human breast tumours as well as uterus, and preliminary evidence suggests that response to endocrine therapy is most likely when tumour tissue contains both ER and PgR (McGuire et al. 1978) .
Here, then, is an illustration of the synthesis of a receptor for one hormone -required for implementation of its action -being dependent on the activity of another hormone -with profound therapeutic implications. But the thought of beginning to discuss the interactions of different hormones, acting in concert or in opposition, leads me rapidly to conclude my lecture.
Conclusion
I have tried to survey some of the funny things that can happen to hormones on the way to their targets.
It is now apparent that many endocrine cells synthesize pro-hormones which they then modify before releasing them into the circulation. The modification may be simple cleavage of a few aminoacids as with PTH, or more complex tailoring as with insulin or ACTH. Fragments of precursor hormones lacking in biological activity may be secreted by endocrine tumours and provide important diagnostic clues. Regulation of hormonal effects on target cells may be achieved by degrading or modifying enzymes, present in the plasma in the case ofTRH or in a separate and distinct organ in the case of vitamin D. And the role of hormone receptors -in cell membranes, cytosol, nucleus or other intracellular organelles -is beginning to gain recognition. Bayliss & Starling, I feel sure, would have been greatly excited by the way their simple concept has been expanded. In preparing this address I have often felt a sense of amazement at the ingenuity of it all.
